Confronto
Lanreotid vs. Octreotide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
108736-35-2
83150-76-9
Peso molecolare
1096.34 g/mol
1019.24 g/mol
Emivita
nessun dato
1.7 h
Sequenza
nessun dato
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Meccanismo d'azione
Lanreotid
Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
1
5
di cui sull'uomo
1
4
Effetti registrati
2
3
Contraddizioni aperte
1
1
Eventi avversi documentati
2
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Lanreotid and Octreotide?
- Lanreotid is classified as "Ricerca (altro)", while Octreotide is classified as "Ricerca (altro)". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lanreotid or Octreotide?
- The highest available evidence level is "RCT sull'uomo" for Lanreotid and "RCT sull'uomo" for Octreotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lanreotid and Octreotide in Germany and the United States?
- Germania: Lanreotid — Su prescrizione, Octreotide — Su prescrizione. Stati Uniti: Lanreotid — Su prescrizione, Octreotide — Su prescrizione. These are factual summaries with source and review date on the individual pages.